Balaglitazone: a second generation peroxisome proliferator-activated receptor (PPAR) gamma (γ) agonist.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Mini-Reviews in Medical Chemistry

• Publication date

  2012-01-31

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.2174/138955712798995048PMID 22372600
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pioglitazone

  2012cited by this paper
• Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel‐group study in patients with type 2 diabetes on stable insulin therapy

  2011cited by this paper
• 7-Hydroxy-benzopyran-4-one derivatives: a novel pharmacophore of peroxisome proliferator-activated receptor alpha and -gamma (PPARalpha and gamma) dual agonists.

  2009cited by this paper
• A comparison of glycemic control, water retention, and musculoskeletal effects of balaglitazone and pioglitazone in diet-induced obese rats.

  2009cited by this paper
• The Risk of Fractures Associated with Thiazolidinediones: A Self-controlled Case-Series Study

  2009cited by this paper
• Reactivation of suppressed RhoB is a critical step for the inhibition of anaplastic thyroid cancer growth.

  2009cited by this paper
• Derivation of a Retinoid X Receptor Scaffold from Peroxisome Proliferator‐Activated Receptor γ Ligand 1‐Di(1H‐indol‐3‐yl)methyl‐4‐trifluoromethylbenzene

  2009cited by this paper
• Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes.

  2009cited by this paper
• The effect of thiazolidinediones on BMD and osteoporosis

  2008cited by this paper
• Pioglitazone and cardiovascular risk. A comprehensive meta‐analysis of randomized clinical trials

  2008cited by this paper
• Dissociation of antihyperglycaemic and adverse effects of partial perioxisome proliferator-activated receptor (PPAR-gamma) agonist balaglitazone.

  2008cited by this paper
• Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.

  2008cited by this paper
• Pioglitazone Use and Heart Failure in Patients With Type 2 Diabetes and Preexisting Cardiovascular Disease

  2007cited by this paper
• Transcription coactivators for peroxisome proliferator-activated receptors.

  2007cited by this paper
• Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.

  2007cited by this paper
• Drug evaluation: rivoglitazone, a new oral therapy for the treatment of type 2 diabetes.

  2007cited by this paper
• Mood-incongruent psychotic features in bipolar disorder: familial aggregation and suggestive linkage to 2p11-q14 and 13q21-33.

  2007cited by this paper
• A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro.

  2006cited by this paper
• A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.

  2005cited by this paper
• The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients.

  2004cited by this paper
• Novel peroxisome proliferator-activated receptor ligands for Type 2 diabetes and the metabolic syndrome

  2003cited by this paper
• Pioglitazone: mechanism of action.

  2001cited by this paper
• A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation.

  1999cited by this paper
• Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ

  1998cited by this paper
• N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.

  1998cited by this paper
• Studies on antidiabetic agents. 11. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents.

  1992cited by this paper
• Identification of a new member of the steroid hormone receptor superfamily that is activated by a peroxisome proliferator and fatty acids.

  1992cited by this paper
• Substituted dihydrobenzopyran and dihydrobenzofuran thiazolidine-2,4-diones as hypoglycemic agents.

  1991cited by this paper
• A potent antihypercholesterolemic agent: [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14643)

  1974cited by this paper

• From Apo to Ligand-Bound: Unraveling PPARγ-LBD Conformational Shifts via Advanced Molecular Dynamics

  2025cites this paper
• A New Era for PPARγ: Covalent Ligands and Therapeutic Applications.

  2025cites this paper
• Recent advances in the design, development and therapeutic applications of PPARγ agonists.

  2025cites this paper
• Decades old glitazones still find niche in drug discoveries as PPAR-γ agonists: medicinal chemistry perspective, structure-activity relationships and therapeutic implications.

  2025cites this paper
• New Quinazolin‐4(3H)‐One–Thiazolidine‐2,4‐Dione Hybrids as Dual Inhibitors of α‐Glycosidase and Aldose Reductase: The Synthetic, In Vitro, and In Silico Approaches

  2025cites this paper
• Quinazolin‐4(3H)‐One‐Based New Glitazones as Dual Inhibitors of α‐Glucosidase and Aldose Reductase: Comprehensive Approaches for Managing Diabetes Mellitus and Its Complications

  2025cites this paper
• Development of phenolic Mannich bases as α-glucosidase and aldose reductase inhibitors: In vitro and in silico approaches for managing diabetes mellitus and its complications.

  2025cites this paper
• Aldose reductase inhibition properties of novel thiazolidin-2,4-diones: In vitro and in silico approach for the treatment of diabetes-related complications

  2025cites this paper
• 4(3H)-Quinazolinone: A Natural Scaffold for Drug and Agrochemical Discovery

  2025cites this paper
• Thiazolidinedione an Auspicious Scaffold as PPAR-γ Agonist: its Possible Mechanism to Manoeuvre against Insulin Resistant Diabetes Mellitus.

  2024cites this paper
• Schizocommunin-inspired heterocyclic hybrid molecules

  2024cites this paper
• Synthetic Strategies of Thiazolidine-2,4-dione Derivatives for the Development of New Anti-Diabetic Agents: Compressive Review.

  2024cites this paper
• Catalyzing the Future of Medicinal Chemistry Research in India.

  2023cites this paper
• Combined In Silico and In Vitro Analyses to Assess the Anticancer Potential of Thiazolidinedione–Thiosemicarbazone Hybrid Molecules

  2023cites this paper
• Thiazolidinedione as a Promising Medicinal Scaffold for the Treatment of Type 2 Diabetes.

  2023cites this paper
• Advances in Synthesis and Biological Activities of Quinazoline Scaffold Analogues: A Review

  2023cites this paper
• Anti-diabetes Research in India: Contributions from Industrial Organizations

  2021cites this paper
• Chemoselective Reactions of Isocyanates with Secondary Amides: One-Pot Construction of 2,3-Dialkyl-Substituted Quinazolinones.

  2021cites this paper
• Importance of quinazoline and quinazolinone derivatives in medicinal chemistry

  2021cites this paper
• Identification of the Anti-Fungal Drug Fenticonazole Nitrate as a Novel PPARγ-Modulating Ligand With Good Therapeutic Index: Structure-Based Screening and Biological Validation.

  2021cites this paper
• Peroxisome Proliferator-Activated Receptors as Superior Targets for Treating Diabetic Disease, Design Strategies - Review Article.

  2021cites this paper
• Thiazolidinedione "Magic Bullets" Simultaneously Targeting PPARγ and HDACs: Design, Synthesis, and Investigations of their In Vitro and In Vivo Antitumor Effects.

  2021cites this paper
• New Drug Discovery and Development: Indian Pharmaceutical Industry

  2021cites this paper
• Microwave-assisted efficient synthesis of Pyrazole-fibrate derivatives as stimulators of glucose uptake in skeletal muscle cells.

  2020cites this paper
• DMSO_A_265399 3627..3635

  2020cites this paper
• Anti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity

  2020cites this paper
• 2,4-Thiazolidinediones as PTP 1B Inhibitors: A Mini Review (2012-2018).

  2019cites this paper
• The Journey of Thiazolidinediones as Modulators of PPARs for the Management of Diabetes: A Current Perspective.

  2019cites this paper
• Catalyst- and Solvent-Free Coupling of 2-Methyl Quinazolinones and Isatins: An Environmentally Benign Access of Diastereoselective Schizocommunin Analogues

  2019cites this paper
• Type II diabetes mellitus and obesity: Common links, existing therapeutics and future developments

  2019cites this paper
• Chlorogenic Acid Functions as a Novel Agonist of PPARγ2 during the Differentiation of Mouse 3T3-L1 Preadipocytes

  2018cites this paper
• Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future

  2018cites this paper
• Pharmacophore Models for Toxicology Prediction

  2018cites this paper
• The Drug Discovery and Development Industry in India—Two Decades of Proprietary Small‐Molecule R&D

  2017cites this paper
• Thiazolidinediones and PPAR orchestra as antidiabetic agents: From past to present.

  2017cites this paper
• PPARγ and Its Role in Cardiovascular Diseases

  2017cites this paper
• PPAR γ and Its Role in Cardiovascular Diseases Mini

  2017cites this paper
• Discovery of Novel Insulin Sensitizers: Promising Approaches and Targets

  2017cites this paper
• Targeting Peroxisome Proliferator-Activated Receptors Using Thiazolidinediones: Strategy for Design of Novel Antidiabetic Drugs

  2017cites this paper
• Serum endotrophin identifies optimal responders to PPARγ agonists in type 2 diabetes

  2016cites this paper
• Design and synthesis of pyrimidinyl acyl thioureas as novel Hsp90 inhibitors in invasive ductal breast cancer and its bone metastasis.

  2016cites this paper
• Product Data Sheet Chemical Properties Product

  2016cites this paper
• Review of the Structural and Dynamic Mechanisms of PPARγ Partial Agonism

  2015cites this paper
• Peroxisome Proliferator-Activated Receptors: Features, Functions, and Future

  2015cites this paper
• Thiazolidinedione compounds: a patent review (2010 – present)

  2015cites this paper
• The role of PPARγ‐mediated signalling in skin biology and pathology: new targets and opportunities for clinical dermatology

  2015cites this paper
• An assembly of structurally diverse small and simple 5-aminomethylene derivatives of 2,4-thiazolidinedione and studies of their biological activity

  2015influential citation
• Chebulagic acid from Terminalia chebula enhances insulin mediated glucose uptake in 3T3-L1 adipocytes via PPARγ signaling pathway.

  2014cites this paper
• Chapter 42 - Insulin, other hypoglycemic drugs, and glucagon

  2014cites this paper
• Diabetes Mellitus and Heart Failure.

  2014cites this paper
• Emerging Role of the Peroxisome Proliferator-Activated Receptors in Hepatocellular Carcinoma

  2014cites this paper
• The first approved agent in the Glitazar's Class: Saroglitazar.

  2014cites this paper
• CMHX008, a Novel Peroxisome Proliferator-Activated Receptor γ Partial Agonist, Enhances Insulin Sensitivity In Vitro and In Vivo

  2014cites this paper
• Identification of Isosilybin A from Milk Thistle Seeds as an Agonist of Peroxisome Proliferator-Activated Receptor Gamma

  2014cites this paper
• New Insights into the PPARγ Agonists for the Treatment of Diabetic Nephropathy

  2014cites this paper
• One feature doesn't fit all: characterizing topological features of targets in signaling networks

  2014cites this paper
• Polyacetylenes from Notopterygium incisum–New Selective Partial Agonists of Peroxisome Proliferator-Activated Receptor-Gamma

  2013cites this paper
• Thiazolidinedione-Induced Fluid Retention: Recent Insights into the Molecular Mechanisms

  2013cites this paper
• On The Horizon: New Oral Therapies for Type 2 Diabetes Mellitus Review Article

  2013cites this paper
• Tissue Distribution and Versatile Functions of PPARs

  2013cites this paper
• Honokiol: A non-adipogenic PPARγ agonist from nature☆

  2013cites this paper
• A review on the development in the field of NIDDM based thiazolidinedione PPARγ agonists.

  2013cites this paper
• Safety of PPAR Agonists

  2013cites this paper
• Targeting adipose tissue

  2012cites this paper